Describing what they do as the "Biological Next Step A New Modality for Precision Medicine" Tezcat Biosciences is an early-stage biopharmaceutical company developing innovative therapies for RAS-mutant cancer patients. Founded to tackle dentification and development of the next generation of precision medicine in oncology, principals of the firm define what they about as developing a new class of therapeutic biologics to treat patients burdened by the most aggressive and recalcitrant cancers. With the firm's lead asset - desigated TZT-102 - TEZCAT's core technology is a protein-based therapeutic delivery platform that penetrates, accumulates in, and is internalized specifically by RAS tumors using a novel escape-resistant targeting mechanism.
